Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide

@article{Mayersohn1995ClinicalPO,
  title={Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide},
  author={Michael Mayersohn and Theodor W. Guentert},
  journal={Clinical Pharmacokinetics},
  year={1995},
  volume={29},
  pages={292-332}
}
SummaryThere has been a resurgence of interest in the use of monoamine oxidase (MAO) enzyme inhibitors for the treatment of depression. Unlike the first-generation MAO inhibitors, the current drugs are readily reversible in their action, resulting in far less concern about interactions with certain foods and drugs which could lead to serious pressor effects. Furthermore, the current drugs are far more selective in their actions as a result of the ability to affect either the MAO-A or the MAO-B… Expand
Moclobemide : An Update of its Pharmacological Properties and Therapeutic Use.
TLDR
Comparative studies have established that moclobemide is better tolerated at therapeutic dosages and has less toxicity in overdose than TCAs and nonselective, irreversible MAO inhibitors, and is also effective in patients with a primary diagnosis of social phobia. Expand
Monoamine oxidase inhibitors. A perspective on their use in the elderly.
Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson's disease. While the classical,Expand
Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
TLDR
The combined use of moclobemide and high doses of sympathomimetic drugs should be approached with caution because of the incidence of adverse events elicited by ephedrine, particularly palpitations and headache. Expand
Monoamine Oxidase Inhibitors
TLDR
Drug tolerability data for the elderly show that moclobemide is one of the most well tolerated compounds, and published data are insufficient to be able to give a conclusive tolerability statement regarding the use of these compounds in elderly people. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
TLDR
Moclobemide inhibited the metabolism of rizatriptan and its active N-monodesmethyl metabolite through inhibition of MAO-A, and may considerably potentiate riz atriptan action. Expand
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
TLDR
The benzamide moclobemide's evolution, pharmacodynamic and pharmacokinetic properties are focused on, including the effects on neurotransmission and intracellular signal transduction, the neuroendocrine system, the tyramine pressure response and animal models of depression are surveyed. Expand
Clinical pharmacology of MAO inhibitors: safety and future.
TLDR
It seems obvious that a greater understanding of the pharmacodynamics and pharmacokinetics of MAOIs could result in improved treatment of the patients in the future, and selective MAO-B inhibitors and RIMAs hold promise as safer alternatives to classicalMAOIs. Expand
Metabolism of the Newer Antidepressants
  • S. Caccia
  • Medicine
  • Clinical pharmacokinetics
  • 1998
TLDR
Several chemically unrelated agents has been developed and introduced in the past decade, to supplement the earlier antidepressants, as well as drugs with distinct neurochemical profiles such as mirtazapine, nefazodone, moclobemide and tianeptine, which may explain the individual variability with all these drugs. Expand
The role of cytochrome P450 2D6 in the metabolism of moclobemide
TLDR
Results indicate that the cytochromal isoenzyme CYP2D6 does not play a major role in the metabolic degradation of moclobemide, and limited CYP 2D6 activities because of a genetic defect or co-medications with CYP1D6 substrates should therefore not give rise to elevated moclOBemide blood levels. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 84 REFERENCES
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
TLDR
The neurochemical profile of moclobemide indicates clearly that this nonhydrazine nonhepatotoxic MAO-A inhibitor represents a novel and safe drug for treatment of affective disorders. Expand
Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
TLDR
In contrast to DHPG, 5HIAA formation was only partially suppressed by moclobemide, suggesting the existence of 5HiaA formation pathways independent of those inhibitable by mClobemides, and a physiological pharmacokinetic-pharmacodynamic model was used to describe MAO-A inhibition as reflected in the alterations of monoamine metabolites. Expand
Safety of moclobemide in clinical use.
The reversible monoamine oxidase-A (MAO-A) inhibitors were developed by researchers in response to safety concerns about the old irreversible MAO inhibitors. Scientists devised this new class ofExpand
An update of recent moclobemide interaction data
  • J. Dingemanse
  • Chemistry, Medicine
  • International clinical psychopharmacology
  • 1993
TLDR
In combination with therapeutic doses of either fluvoxamine or fluoxetine, moclobemide did not provide any indication of a serotoninergic syndrome, so that no wash-out period is needed when switching from a selective serotonin re-uptake inhibitor to moclOBemide or vice versa. Expand
Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.
The single-dose kinetics of the MAO-inhibitor p-chloro-N-(2-morpholinoethyl)-benzamide (moclobemide, Ro 11-1163) following oral and i.v. administration to six healthy subjects is described. TheExpand
The new generation of monoamine oxidase inhibitors.
  • A. Cesura, A. Pletscher
  • Medicine
  • Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 1992
TLDR
In subjects with Parkinson's disease the MAO-B inhibitor L-deprenyl exerts a L-dopa-sparing effect, prolongs L- dopa action and seems to have a favorable influence regarding on-off disabilities. Expand
Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
TLDR
It is suggested that therapeutic doses of moclobemide up to 300 mg daily can be given 24 hours after the last dose of treatment with either amitriptyline or clomipramine without major risks. Expand
Disposition Kinetics of Moclobemide, a New Mao‐A Inhibitor, in Subjects with Impaired Renal Function
TLDR
There does not appear to be any need to alter the normal dosing regimen of moclobemide in subjects with renal impairment in order to achieve drug concentrations similar to those in healthy subjects. Expand
Interaction studies with moclobemide
TLDR
Evidence is provided that amitriptyline can replace or be added to moclobemide without any sign of impaired tolerance, need for dose reduction or a therapy‐free interval, and replacement of the older, irreversible MAO inhibitors by a TCA is held to be dangerous and to require a therapy-free interval. Expand
Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
TLDR
It is suggested that DHPG in plasma may be a useful indicator of the magnitude and duration of MAO-A inhibition in man. Expand
...
1
2
3
4
5
...